Pharmacological profile of BR-931, a new hypolipidemic agent that increases high-density lipoproteins
- 1 May 1978
- journal article
- research article
- Published by Elsevier in Atherosclerosis
- Vol. 30 (1), 45-56
- https://doi.org/10.1016/0021-9150(78)90151-x
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- HIGH-DENSITY-LIPOPROTEIN CHOLESTEROL AND OTHER SERUM LIPIDS IN A NEW ZEALAND BIRACIAL ADOLESCENT SAMPLEThe Lancet, 1977
- On the rise in low density and high density lipoproteins in response to the treatment of hypertriglyceridaemia in type IV and type V hyperlipoproteinaemiasAtherosclerosis, 1977
- The Effect of Hypolipidemic Drugs on Plasma LipoproteinsAnnual Review of Pharmacology and Toxicology, 1977
- Clofibrate-induced low density lipoprotein elevation therapeutic implications and treatment by colestipol resinAtherosclerosis, 1976
- Clofibrate and niacin in coronary heart diseaseJAMA, 1975
- PLASMA-HIGH-DENSITY-LIPOPROTEIN CONCENTRATION AND DEVELOPMENT OF ISCHÆMIC HEART-DISEASEThe Lancet, 1975
- A potent antihypercholesterolemic agent: [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio]acetic acid (Wy-14643)Cellular and Molecular Life Sciences, 1974
- Metabolic relationships among the plasma lipoproteinsJCI Insight, 1972
- Triton‐induced hyperlipidemia in rats as an animal model for screening hypolipidemic drugsLipids, 1972
- Hypocholesterolemic 5-substituted tetrazolesJournal of Medicinal Chemistry, 1969